All right. Good day, everybody. Welcome to UBS Global Biopharma Conference in London. Next company with me here, Incyte. I am really excited to present Pablo Cagnoni, who is the President and Global Head of R&D, excuse me, and Suky Upadhyay, who is EVP and Chief Financial Officer. Thank you guys for joining us. My name is Ash, Ash Verma. For those of you who do not know me, I cover SMID-cap Biotech and Spec Pharma at UBS. I think there is a lot of focus on just the pipeline build-out for Incyte, a lot of programs that you have provided recent updates around. If you can maybe just give some high-level thoughts to start off with, and then we can dive more in specific into the assets.
Certainly, and thank you. Thank you for having us here today. We have two big pillars of the strategy that we are executing against over the next few years. One is to continue to grow the ex-JAKAFI core business. That is a key component of the strategy. Drugs that are currently commercialized, like OPZELURA, MONJUVI, NIKTIMVO, ZYNYZ, grow those brands as much as possible in the next few years, including, hopefully early 2027, the launch of povorcitinib as well in that bucket. That, together with the conversion of JAKAFI to JAKAFI XR, will provide a floor and will continue to support the company going forward through the LOE of JAKAFI at the end of 2028. The second pillar of the strategy is executing on the pipeline, as you pointed out. We have a very exciting pipeline. We have a number of drugs already in pivotal trials.
We provided an update recently, and I am sure we will spend time talking about the individual programs. We have our G12D program in phase III. We have latarcibart, our Protein S modulator, in phase III. TGF-beta by PD-1 in phase III as well. Obviously, we have more povo launches coming up as well, and of course, our CALR program in phase III as well. Those programs will start producing pivotal data and launches in the 2028- 2029, and beyond. The goal is to have a fast-growing company with a double-digit CAGR coming out of the LOE after that, driven a bit by the pipeline that I am sure we will discuss in more detail.
Great. That is awesome. So yeah, I guess, talking about the mutant CALR, Pablo, there has been a lot of focus on this first-line MF data that we are going to get at the ASH conference. As much as you say to people that, do not focus on the abstract, people definitely look at that, right? Just if you can talk a little bit about what is the data that we saw and what more to expect at the ASH conference, and then I will ask some more specific follow-ups.
Earlier this year at the EHA meeting, we reported, as you know, a group of patients that we call JAK ineligible, right. Those are previously untreated with a JAK inhibitor, but they were ineligible, usually because of anemia, so it is a different population of patients. What you are going to see for the first time at ASH is a group of patients that are JAK eligible with previously untreated MF. It is a group of about 40 patients that we are going to present with a firm and a follow-up at this point, and there are two sets of patients because we randomized them to single agent 989, our CALR antibody, and the combination of 989 with JAKAFI.
The reason why we try not to focus on the abstract right now is we have a lot more follow-up and more patients in the presentation, and that is the mature data that we should focus on. One way to start thinking about the data is if you look at the ineligible cohort that we presented at EHA, that is sort of like a floor that you should expect, right. Because those are ineligible patients, and there is no combination JAKAFI arm in that group. The ASH data will be true frontline patients. It is really important because it is a piece of data that we need to finalize the design of the frontline MF study that we will initiate in the first half of 2027. So that is why it is a really important data release for us, and why we are so excited about ASH coming up in just a few weeks.
Yeah. The way that, I know in the abstract, it is kind of just like getting early glimpse of the data, but you have combined the JAK ineligible and true naive patients, right? When you start to sort of parse that through, what should we expect, either on the SVR35 or TSS50? Yeah, I think you said that JAK ineligible should be the floor for the efficacy levels, on both the metrics, or?
You should expect that the data in JAK eligible patients to be better than the data in ineligible patients. I am not going to get into how much better it is going to be or could be. We are going to have to wait a couple of weeks. But you should expect that that is the floor where the efficacy of this drug would be. The other important factor in true eligible patients is going to be the impact of 989 on anemia in these patients, which again, you got a glimpse of that in the second-line patients and in the ineligible patients back at EHA.
Now, you will see the impact of 989 on anemia improvement in patients with previously untreated MF, and I think that is a really important piece of data that I think should also be reassuring, because 989 is designed to basically normalize hematopoiesis in these patients, to suppress the malignant clone and allow the wild-type clone to re-expand and take over. That is what you will see when we look at the anemia data.
Yeah. Just if I talk about the difference between the monotherapy 989 and the rux combo, I mean, so far, the data that we have seen, not a big stark difference, I guess. When you think about it, I am sure we will see more data, but when you think about the kind of unity of the combo, where does that fit in the broader picture?
We know what JAKAFI does very well. It acts very quickly, it alleviates symptoms very quickly, and it has established a certain rate of SVR35. Although, we know that in CALR-mutated patients, the SVR35 on JAKAFI from two different studies, about 20% or 22%. It is not very good at shrinking spleens in CALR-positive patients, and we know that. It is fairly good at improving symptoms in that population, and it does so quickly. The problem with JAKAFI is more than 40% of patients develop anemia, and that happens pretty quickly. A lot of patients also develop thrombocytopenia. When we combine it with 989, you should expect maybe improvement on SVR35 over what 989 does alone. But the challenge might be that it blunts a little bit the improvement in anemia that 989 provides, which we think is such an important part of the value proposition for 989.
We will have to see. We will look at all the data with single agent and with combination, and we will, based on that data, make the decision on the design of the phase III trial, which, as I mentioned, we will launch in the first half of 2027. The other important piece of evidence that we need to design that trial is a continued conversation with FDA. As we pointed out, I believe during the earnings call, we think it is time for the FDA to reconsider the approvable endpoints in patients with MF. Historically, since the approval of JAKAFI, in fact, the standard endpoints have been SVR35 and TSS50. You know the history. There has been a lot of attempts to beat JAKAFI in that setting. They have been unsuccessful. 989 has a fundamentally different mechanism of action, right. It is about, again, eradicating the malignant clone and normalizing hematopoiesis.
We think that needs to be studied with a different set of endpoints. What we are proposing is an endpoint, a composite endpoint that takes into account hemoglobin, platelets, blasts in peripheral blood, and spleen volume. If you meet all four, you succeed. If you fail even one of the four, you don't meet the endpoint. We think that is, A, based on data in the literature, more predictive of survival in the long run in these patients, and we think it defines better the benefit that 989 provides to patients. We have a meeting scheduled in the early part of the first quarter with the FDA to discuss that. There's a special group at the FDA called the Surrogate Endpoints Team. We'll have that conversation, and then we'll provide an update.
If they don't accept that, we'll run a frontline study with SVR35 and TSS50, but we think that might be a better way to go. Stay tuned.
Yeah. I guess, yeah, that'll be an important update to sort of understand the trial design, and when you launch the study, which I believe you're planning for 2027?
It will be the first half of 2027, yes.
Right. Okay. I mean, just for the ASH conference update, the efficacy metric that you talked about, the 20%-22% SVR35 that JAKAFI has seen from this COMFORT study that was done way back, right?
Mm-hmm. Yeah.
Is there a more recent relevant benchmark, you think? If drugs was used as a control arm in some study, at least you get a sense of how the Type 1 versus Type 2, or non-Type 2—
Yeah. If you look at the pelabresib study, the MANIFEST-2 phase III trial that was published, and you go to the additional, to the supplementary materials in the back, there's a forest plot, and it shows the SVR35 in CALR-positive patients. It doesn't show it by mutation subtype, but it does show that it's And it's not a number, but there's a bar in the forest plot, and it's about 20%-22%. So it's the same number that was reported with the JAKAFI study that you mentioned. What is not there is the TSS50 CALR-mutated patients, but the SVR35 is there, and that's a very recent comparable. So, we're confident. Besides, JAKAFI is a JAK inhibitor. CALR is a driver mutation in this patient, so it's not surprising that it doesn't work as well as in JAK-mutated patients, which are the other two-thirds of the population with MF.
All right. Okay. Yeah. The way that you've seen for ET, I guess the trial design has panned out in a way that you're having to increase the dose level in non-Type 1 patients, right? Do you think in MF we can start to see that type of construct as well?
Slightly different, but yeah. In ET, just to remind everyone, patients start at 750. If you do not have a response by the end of the first cycle, basically one month, you can escalate to 2,500. The reason for that is we have seen data and we modeled the PK exposure response data and suggest very clearly, as you point out, that non-Type 1 patients may respond to a higher dose. Some Type 1 as well, by the way. That is why there is an escalation, because in ET, what we have shown with 989 is a rapid normalization of the platelet count. That tells you very quickly whether the drug is working or not. In MF, it takes a little bit longer for the efficacy to set in.
What we are planning to do in MF is we will have a starting dose of 750 in Type 1 from the beginning, and the starting dose of 2,500 for non-Type 1 from the beginning. That quick dose escalation in MF is not practical because you do not have as good a PD marker as platelet normalization, which you see in ET.
Yeah. In terms of the safety profile, yeah, anything that you are watching out for adverse events of interest in the mono or combo arms?
The combination with JAKAFI, you will see a lot of JAKAFI-driven events. I have to tell you, it is pretty remarkable, this drug. Been in the clinic for more than two years now. We have patients with ET for more than two years on drug. Maybe one or two patients have discontinued because of an adverse event. I mean, it has been a very well-tolerated drug. When we report events, we report everything that these patients report, obviously, and they have background ET or MF, and that leads to reporting of adverse events. When you think about things that are related to the study drug, it is turning out to be a very, very well-tolerated drug with minimal number of patients withdrawing due to an adverse event.
When we think about the market opportunity here in the first line, how much of that is JAK-inhibitable patients versus the true naive?
Look, if you think about MF, you have to think it is about a third of the population, right. They are CALR-mutated patients. Of those, Type 1 versus non-Type 1 is around two-thirds, three-quarters are Type 1, depending on the source. The most recent blood review on this shows about 75% of the patients, about three-quarters. So that is about 20%-25% of all MF patients. It is a quarter of the JAKAFI market, one way to look at it. The difference is the duration of therapy is likely to be longer because it is a biologic, and it will launch three, four years from now. It will launch at a different price point than JAKAFI. JAKAFI is the most inexpensive JAK inhibitor in the market right now.
That very quickly, you can put that together, gets to a very healthy number when you think about the potential market that we can build with 989.
Yeah. When you think about sort of the broader commercial opportunity for 989, how much of that is MF versus ET?
Well, ET, today, the frontline therapy is hydroxyurea. Some patients do get interferon. Second line, interferon doesn't work very well. The rate of hematologic response with interferon and hydroxyurea failures in second line is about 33% that has been reported. We're showing rates of over 70% in that setting, and in Type 1 patients, it's even higher. So we think that once 989 is approved in patients with ET, I think the pressure to discontinue hydroxyurea and switch patients to 989 will build up very quickly, because a lot of patients are intolerant to hydroxyurea. It does have some toxicities, and as I just mentioned, not all patients respond with normalization of platelets. You have to monitor white cell count, toxicity, et cetera. So, we think there is a broad opportunity in ET, which is probably as big, if not bigger, than the opportunity in MF.
Great. Okay. I wanted to ask your views on, we saw this recent M&A transaction. It was actually yesterday, right? Lilly buying this another mCALR program. To the extent that you can comment on, yeah, like what do you think about the molecule, where your differentiation is with some of the next gen that are starting to come out?
Absolutely. The company you mentioned, it's Calytrix. First of all, I think the fact that there continues to be interest in the CALR mutation space is really reassuring and, in a way, flattering. We started this space three years ago by putting 989 into the clinic. And it's remarkable, right. The mutation was described and published for the first time 13 years ago in a New England Journal paper article, and from there, we fast-forward to only 13 years later, we have a novel medicine, 989, in pivotal trials, and we have two more. Sounds like they're either about to enter clinical trials or so. We don't know much about Calytrix. It's a biparatopic antibody, binds to different epitopes. There's very little disclosed data, how much of the company has said, so it's hard for us to assess exactly what the role is going to be going forward.
What I would tell you, though, is that 989 is already, as I mentioned, pivotal trials, second line MF, going to start for 989 early next year or first half of next year. At ASH, you are going to see 798, the preclinical package for our next-generation CALR antibody, which dramatically improves the properties of 989. In fact, when you look at what has been disclosed in CALR antibodies, I would argue that 798 redefines the category, because it really has 70 times more potency against non-Type 1 mutations than 989. It has a predicted half-life in humans about 50 or 60 days. So you are looking at a very short dose escalation trial, because you only need a few cohorts to get to the right dose. It is going to be given subcu in a pen, monthly or less often.
It has all the properties you need and the right approach here. 989 is turning out to be a great drug for these patients. We will move it forward, we will get it approved and launched. But very soon after, we will come with 798, which, as I mentioned, I think it is a vast upgrade there. It will be in the clinic early 2027, and if everything goes well, we should be in a position to start pivotal trials in the middle of 2028.
All right. Yeah. I know there is another competitor that people are watching out for, Damora's program, that will have data from mid-2027 onwards. What do you think the next gen that you have would compare to what Damora is trying to solve for? Just kind of like equipotent on Type 1 and non-Type 1?
Yes. I mean, we have seen preclinical data, same as for 798, and we will show the full preclinical package at ASH. What you have today is only what is in the abstract for 798. Based on what we have seen from Damora in presentations, it looks like they made a really good antibody. We still think that 798 has better properties, is more potent against non-Type 1, and it has a longer half-life. So we still think we have better properties than our competitors. Our focus here, just to be clear, on the CALR program in general, 989 and 798, is to execute on that plan. There will be competition. We think we have the right tools against the competition. 989 is the first one, and we think we will come with 798, with probably what looks today, based on preclinical data, the best-in-class CALR antibody.
Okay. Maybe switching topics to G12D. You have shared some data here, and now starting to look pretty competitive, based on some of the other programs that exist out there. I mean, there is a lot of action happening in the pancreatic market, as you know. I think one of the things that we are starting to hear from physicians is that, as daraxonrasib starts to move into first front line and be clustered in combination with zoldonrasib, then how does the first-line market opportunity evolve, and what space does that leave for agents that are exclusively G12D?
Yeah. It is a great question. If you look at the last 25 years in oncology, there has been a journey towards more precisely molecular targeted therapy. I think when you have the tools, that is the way the field has evolved, whether it is lung cancer, breast cancer, obviously hematologic as well, is try to find, try to give the right drug to the right patient at the right time. We think 12D, 734, a 12D inhibitor, fits with that paradigm. I think if you fast-forward 5+ years and you look at the landscape and the options in front of newly diagnosed patients with pancreatic cancer, I think there will be an array of options. That is the way we see it play.
I think there will be a lot of patients and physicians who will prefer a precisely targeted therapy, a 12D inhibitor, perhaps with chemotherapy, perhaps with a PRMT5 inhibitor, perhaps with a PARP inhibitor, perhaps with a pan-RAS inhibitor. Other patients will prefer just a single-drug approach, for example, a pan-RAS or a G12D. This will all be options that I think will be in front of patients, and depending on the fitness of the patient and the aggressiveness of the disease, I think that different choices will be made. Today, when I look at the data, I still find a combination of a 12D inhibitor with chemotherapy to be the most active combination in terms of response rates. At least what we know today. The durability data is coming in, and it is looking very good so far, but we certainly need more time.
I am not saying that the market would be 100% chemotherapy plus a 12D, but I do think it is going to be a substantial part of the market. Because of what I described as an array of combinations, our goal has been to test a number of different combinations with our G12D inhibitor, and that is what we are doing. We are in pivotal trials with chemotherapy, with two types of chemotherapy, Gem/Nab and modified FOLFIRINOX. We just announced a collaboration with BMS to test our molecule with a PRMT5 inhibitor, a collaboration with Genmab to test with panitumumab, their EGFR inhibitor, and a collaboration with Synnovation to test with selective PARP1 inhibitor. Because we think building those combinations will matter to give patients options and find different ways to address resistance.
We are discussing further combinations. An obvious one is pan-RAS, which is the one you brought up, and we are having conversations to find the right partner for that collaboration as well. You should hear more announcements from us in the next few months. That is the way I see the field evolving.
Okay. I mean, when you think about the frontline PDAC opportunity, is there some sort of a bifurcation in the market, like how you are alluding to, that certain patients would be good candidates for chemo combo options, like with G12D, as opposed to other patients just being that could tolerate a skin rash with daraxonrasib or adagrasib?
Perhaps. I think that would be a patient choice. First, we need to make sure that both data sets are comparable. We are going to be comparing side-by-side two different clinical trials. That is sometimes challenging. My assumption is that both approaches are going to be better than conventional chemotherapy, but perhaps that is not true. So let us wait for that data, number one. Safety profiles, as you pointed out, are different. Efficacy might be different in terms of speed of response, for example. Honestly, I think that trying to predict how those trials will come out, it is difficult. My, I am going to call it a prediction, is that all these approaches are going to improve the standard of care in pancreatic cancer, and I think all the approaches will be available to patients.
Our goal is to make 734, our G12D inhibitor, a partner to multiple approaches available to patients three, five, seven years from now. If we do that, we will establish a presence in the market, and I think that is the right approach.
Great. No, this is good. All right, Suky, maybe I'll switch it over to you now.
Yeah, sure.
I mean, there has been a lot of discussion around just a lot of the R&D programs that you have, obviously, like big diversification happening. Just if you can give me a little bit of a sense of where you think the R&D spend is right now? How does it start to sort of ramp up as you go into next year, as you fund these programs?
Yeah. First of all, I think it's just new to the company. It's pretty exciting how much progress Incyte's made in a short amount of time in 2027, with all the late-stage programs that Pablo has just spoke about. With that, the number of phase IIIs that we have underway right now, it would not be surprising to see an increase in R&D as we go into 2027. In fact, if you go back to our third quarter call, and you look at the implied guidance we provided on OpEx, you'll see that the fourth quarter is going to step up pretty significantly. That's primarily all R&D, and that direction is going to continue to flow into 2027. It's not going to be linear.
It's going to be relatively dynamic as the portfolio continues to matriculate, and we're going to continue to be disciplined and look for offsets elsewhere, as we think about resource allocation.
Okay. Separately, it's not related to each other, but just on JAKAFI XR conversion, if you can talk about what has been the early feedback on that conversion, and where do we see that building out from here?
Yeah. So far, we're in line with our expectations. We ended the third quarter with about 3% conversion to date. If that trajectory continues, we expect to be safely in our 10%-30%, as we said, at the expiration of JAKAFI. The good thing is we're seeing a good mix of existing JAKAFI patients as well as a good, healthy amount of new patients coming on to XR. So I'd say it's steady as she goes. Still early days, but we like what we're seeing.
Great. Another quick one, just in terms of the expectation for povo and its launching for HS next year. Yeah, I guess, big market, but how are you thinking about this launch? What's sort of the launch preparedness for that?
Yeah, it's pretty exciting. Launch has actually, investments have been underway all through 2027. Hopefully we get the label soon. We expect that to be sometime in the first quarter with a clear understanding of what that full label is going to look like. Coverage has been underway. When you put all of those factors together, by the time you get to launch somewhere in the first quarter, you get the full access, you're talking about a partial year of uptake in 2027. We've kind of sized it at, think about it as being about 5%-10% of peak sales in year one. But yeah, everything seems to be tracking as expected.
Great. I know you're ultimately, just like with the diversification of the pipeline, trying to solve for the JAKAFI LOE, and as you get closer to that, is there some sort of rationalization for some pipeline programs that you think are not going to make the cut? Do you start to sort of focus on that? We saw the CDK2 announcement. Is there more sort of refining of the pipeline that happens over the next few years?
Let me just share one thought first.
Yeah.
We're not solving for the LOE. We're solving for post-LOE growth.
Yeah.
It is a really important difference. The LOE is two and a half years away. The solution for the LOE, or the partial solution for the LOE, is to grow the ex-JAKAFI core business, which is going very well and is growing at a very healthy rate. What we are solving is to have a fast-growing company post-LOE, and that is why we are investing in the pipeline, as Suky summarized. But, we will continue to be very thoughtful about capital allocation. We looked at every program with the same lens, which is this program going to deliver value to patients, and is it going to deliver value to shareholders? The CDK2 program, which we liked that program because it would provide an oral, well-tolerated option for patients with ovarian cancer, but became increasingly clear that the competitive landscape was shifting under us.
The most recent update was right before the ESMO conference. One of our competitors, Genmab, reported data with their ADC in ovarian cancer, what I would characterize as stellar data, with a hazard ratio for survival of 0.4 something. That, together with the execution of that trial, was becoming increasingly complex because there is now five ADCs in that setting, plus the fact that the readout for that trial was in 2032. When you put all that together, we decided there were better places in our pipeline to allocate that capital, and we decided to stop the program. We are going to continue to have that discipline throughout the next several years.
Yeah. I mean, as you head more towards this, yeah, sort of the driving the growth coming out of LOE, I guess, is there, on the SG&A side, is there any optimization possible? I mean, R&D, obviously, you need that to fuel the growth for the pipeline.
Yeah. We think about our capital allocation priorities in two major ways. Pablo talked about this at the beginning of the discussion. One is around getting that core beyond JAKAFI to that $3 billion or $4 billion level by the time we hit the LOE. As we think about that, we are investing significantly against the new product launches, the recent launches we have had around JAKAFI XR as well. Inside of that, there are trade-offs. So we are moving money from more mature brands into our launch products. We are looking for areas, even inside the investment, how do you do it more efficiently inside of SG&A, and how do you continue to leverage your G&A? So these are all trade-offs that we are making, not only in the R&D portfolio, but really throughout the rest of the P&L.
Great. With that, we are out of time. Thank you so much. Super helpful discussion, and thanks for joining us for our conference.
Thank you for having us.
Thanks, Ash.